SCHEMBL5536751

SCHEMBL5536751

NC(=O)Nc1ccc([O])cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PEPD P12955 1/20 0.67
ALDH1A1 P00352 3/20 0.64
NPC1 O15118 1/20 0.64
MAPT P10636 2/20 0.59
GAA P10253 1/20 0.59
GFER P55789 1/20 0.59
KIF11 P52732 8/20 0.57
MEN1 O00255 1/20 0.57
LMNA P02545 1/20 0.57
KMT2A Q03164 1/20 0.57
GLA P06280 1/20 0.52
HSD17B10 Q99714 1/20 0.48
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
RAB9A P51151 1/20 0.44
F2 P00734 1/20 0.43
PRSS1 P07477 1/20 0.43
PRSS2 P07478 1/20 0.43
PRSS3 P35030 1/20 0.43
TMPRSS6 Q8IU80 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5062623 0.89 PEPD (0.80) PEPDALDH1A1NPC1MAPTGAA
SCHEMBL6879129 0.80 MAPT (0.70) PEPDALDH1A1NPC1MAPTGAA
SCHEMBL1322717 0.80 PEPD (1.00) PEPDALDH1A1NPC1MAPTGAA
SCHEMBL11760586 0.78 PEPD (0.64) PEPDALDH1A1NPC1MAPTGAA
SCHEMBL6938372 0.78 PEPD (0.64) PEPDALDH1A1NPC1MAPTGAA
SCHEMBL14047972 0.78 PEPD (0.64) PEPDALDH1A1NPC1MAPTGAA
SCHEMBL81433 0.78 KIF11 (0.88) PEPDALDH1A1NPC1MAPTGAA
SCHEMBL2235161 0.78 PEPD (0.64) PEPDALDH1A1NPC1MAPTGAA
SCHEMBL5533070 0.78 PEPD (0.64) PEPDALDH1A1NPC1MAPTGAA
SCHEMBL8379303 0.78 PEPD (0.64) PEPDALDH1A1NPC1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PEPD 4549/4885ALDH1A1 355/4885NPC1 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.